16 completed, 3 terminated, 1 withdrawn. 10 Phase 3, 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 6, Terminated 3, Withdrawn 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 4 | Completed 4 |
Follow bococizumab: new trials by email Literature Review of bococizumab trials Research Report on bococizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects Bococizumab, Placebo - Primary Hyperlipidemia or Mixed Dyslipidemia | Phase 3 | Withdrawn | Pfizer | 2016-10-31 | 2017-12-02 | |
| Bococizumab HIV Evaluation (B-HIVE) Study Bococizumab, Placebo - Dyslipidemia, Cardiovascular Disease | Phase 3 | Terminated | University of California, San Francisco | 11 | 2016-08-01 | 2019-06-19 |
| Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 299 | 2015-06-01 | 2017-12-19 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 746 | 2014-10-28 | 2018-07-31 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316) - Hyperlipidemia | Phase 3 | Completed | Pfizer | 184 | 2014-06-01 | 2017-12-14 |
| Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm Bococizumab (PF-04950615; RN316) - Hypercholesterolemia | Phase 1 | Completed | Pfizer | 75 | 2014-04-01 | 2019-05-31 |
| Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects Bococizumab (PF-04950615;RN316), Placebo, Ezetimibe - Hypercholesterolemia | Phase 2 | Completed | Pfizer | 218 | 2014-03-01 | 2019-02-08 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 2139 | 2013-10-29 | 2018-07-31 |
| The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects bococizumab (PF-04950615), Placebo - Cardiovascular Disease | Phase 3 | Terminated | Pfizer | 10564 | 2013-10-29 | 2019-05-01 |
| The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects bococizumab (PF-04950615), Placebo - Cardiovascular Disease | Phase 3 | Terminated | Pfizer | 16784 | 2013-10-29 | 2018-07-11 |
| A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia Bococizumab (PF-04950615;RN316), Placebo - Heterozygous Familial Hypercholesterolemia | Phase 3 | Completed | Pfizer | 370 | 2013-10-23 | 2017-06-26 |
| Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615;RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 711 | 2013-10-01 | 2017-05-17 |
| Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316) - Hypercholesterolemia | Phase 2 | Completed | Pfizer | 354 | 2012-07-01 | 2017-12-05 |
| A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects PF-05335810 Dose A, PF-05335810 Dose B, Placebo - Hypercholesterolemia | Phase 1 | Completed | Pfizer | 133 | 2012-07-01 | 2018-12-04 |
| A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia PF-04950615 (RN316) - Hypercholesterolemia, Dyslipidemias | Phase 1 | Completed | Pfizer | 49 | 2011-10-01 | 2018-07-23 |
| A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins Placebo, Statin, PF-04950615 (RN316) - Hypercholesterolemia, Dyslipidemia | Phase 2 | Completed | Pfizer | 93 | 2011-07-01 | 2017-10-11 |
| A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins Placebo, PF-04950615 (RN316) - Hypercholesterolemia, Dyslipidemia | Phase 2 | Completed | Pfizer | 46 | 2011-06-01 | 2017-11-08 |
| Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia PF-04950615 (RN316) - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | Pfizer | 68 | 2011-02-01 | 2019-01-22 |
| Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin 4 mg/kg, 0.5 mg/kg - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | Pfizer | 25 | 2010-07-01 | 2018-03-01 |
| A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects RN316 - Healthy | Phase 1 | Completed | Pfizer | 48 | 2009-11-01 | 2012-07-04 |
Hypercholesterolemia (10) · Hyperlipidemias (9) · Dyslipidemias (7) · Cardiovascular Diseases (3) · Myocardial Infarction (2) · Stroke (2) · Lipid Metabolism Disorders (1) · Metabolic Diseases (1)
Pfizer (19) · University of California, San Francisco (1)
United States (18) · Canada (9) · Poland (5) · United Kingdom (5) · Czechia (4) · Finland (4) · Italy (4) · Netherlands (4) · South Korea (4) · Spain (4) · Australia (3) · Colombia (3) · France (3) · Germany (3) · Hungary (3)
PMID 37994400, PMID 28181260, PMID 28304227, PMID 29685591, PMID 35277540, PMID 37658997, PMID 29037448, PMID 28304242, PMID 29716940, PMID 25784512, PMID 28539539, PMID 28636184, PMID 31529318, PMID 31549625
2014 (1)